{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:50:35Z","timestamp":1787309435710,"version":"build-2736575974"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA250503"],"award-info":[{"award-number":["R01-CA250503"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA268518"],"award-info":[{"award-number":["R01-CA268518"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA207701"],"award-info":[{"award-number":["R01-CA207701"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170500"],"award-info":[{"award-number":["RP170500"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Mantle cell lymphoma (MCL) has a poor prognosis and high relapse rates despite current therapies, necessitating novel treatment regimens. Inhibition of SRC-3 show effectiveness\n                    <jats:italic>in vivo<\/jats:italic>\n                    and\n                    <jats:italic>in vitro<\/jats:italic>\n                    in other B cell lymphomas. Additionally, previous studies have shown that SRC-3 is highly expressed in the lymph nodes of B cell non-Hodgkin\u2019s lymphoma patients, suggesting SRC-3 may play a role in the progression of B cell lymphoma. This study aimed to investigate novel SRC-3 inhibitors, SI-10 and SI-12, in mantle cell lymphoma. The cytotoxic effects of SI-10 and SI-12 were evaluated\n                    <jats:italic>in vitro<\/jats:italic>\n                    and demonstrated dose-dependent cytotoxicity in a panel of MCL cell lines. The in vivo efficacy of SI-10 was confirmed in two ibrutinib-resistant models: an immunocompetent disseminated A20 mouse model of B-cell lymphoma and a human PDX model of MCL. Notably, SI-10 treatment also resulted in a significant extension of survival in vivo with low toxicity in both ibrutinib-resistant murine models. We have investigated SI-10 as a novel anti-lymphoma compound via the inhibition of SRC-3 activity. These findings indicate that targeting SRC-3 should be investigated in combination with current clinical therapeutics as a novel strategy to expand the therapeutic index and to improve lymphoma outcomes.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0289902","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:24:50Z","timestamp":1714397090000},"page":"e0289902","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma"],"prefix":"10.1371","volume":"19","author":[{"given":"Imani","family":"Bijou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Lonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert W.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-7919","authenticated-orcid":true,"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"pone.0289902.ref001","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"JM Vose","year":"2017","journal-title":"American Journal of Hematology"},{"key":"pone.0289902.ref002","doi-asserted-by":"crossref","first-page":"588314","DOI":"10.3389\/fonc.2020.588314","article-title":"Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995\u20132016: A SEER-Based Analysis","volume":"10","author":"H Wu","year":"2020","journal-title":"Front Oncol"},{"key":"pone.0289902.ref003","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"A Kumar","year":"2019","journal-title":"Blood Cancer J"},{"key":"pone.0289902.ref004","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"S Rule","year":"2019","journal-title":"Haematologica"},{"key":"pone.0289902.ref005","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Y Song","year":"2022","journal-title":"Blood"},{"key":"pone.0289902.ref006","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2019852368","article-title":"Acalabrutinib for mantle cell lymphoma","volume":"133","author":"TE Witzig","year":"2019","journal-title":"Blood"},{"key":"pone.0289902.ref007","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1073\/pnas.0409578102","article-title":"Identification of target genes in breast cancer cells directly regulated by the SRC-3\/AIB1 coactivator","volume":"102","author":"P Labhart","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0289902.ref008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41586-018-0018-1","article-title":"Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer","volume":"556","author":"S Dasgupta","year":"2018","journal-title":"Nature"},{"key":"pone.0289902.ref009","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1172\/JCI61492","article-title":"ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion","volume":"122","author":"W Long","year":"2012","journal-title":"J Clin Invest"},{"key":"pone.0289902.ref010","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1158\/0008-5472.CAN-04-4076","article-title":"SRC-3 Is Required for Prostate Cancer Cell Proliferation and Survival","volume":"65","author":"H-J Zhou","year":"2005","journal-title":"Cancer Research"},{"key":"pone.0289902.ref011","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev-med-051812-145316","article-title":"Nuclear Receptor Coactivators: Master Regulators of Human Health and Disease","volume":"65","author":"S Dasgupta","year":"2014","journal-title":"Annual Review of Medicine"},{"key":"pone.0289902.ref012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejphar.2016.06.048","article-title":"Steroid receptor coactivator-3 is a pivotal target of gambogic acid in B-cell Non-Hodgkin lymphoma and an inducer of histone H3 deacetylation","volume":"789","author":"Z Zhao","year":"2016","journal-title":"European Journal of Pharmacology"},{"key":"pone.0289902.ref013","doi-asserted-by":"crossref","first-page":"eabh2169","DOI":"10.1126\/sciadv.abh2169","article-title":"A single-cell type transcriptomics map of human tissues","volume":"7","author":"M Karlsson","year":"2021","journal-title":"Sci Adv"},{"key":"pone.0289902.ref014","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1073\/pnas.1604274113","article-title":"Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3","volume":"113","author":"X Song","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0289902.ref015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-20-0402","article-title":"Development of improved SRC-3 inhibitors as breast cancer therapeutic agents","volume":"28","author":"L Qin","year":"2021","journal-title":"Endocrine-Related Cancer"},{"key":"pone.0289902.ref016","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"LA Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"pone.0289902.ref017","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"J Kale","year":"2018","journal-title":"Cell Death Differ"},{"key":"pone.0289902.ref018","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/s41375-022-01627-9","article-title":"Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma","volume":"36","author":"YJ Thus","year":"2022","journal-title":"Leukemia"},{"key":"pone.0289902.ref019","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.15108","article-title":"Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects","volume":"181","author":"O Hershkovitz-Rokah","year":"2018","journal-title":"Br J Haematol"},{"key":"pone.0289902.ref020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2021.05.008","article-title":"Bufalin targets the SRC-3\/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer","volume":"513","author":"J Chen","year":"2021","journal-title":"Cancer Letters"},{"key":"pone.0289902.ref021","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1677\/erc.1.01222","article-title":"Tamoxifen-induced ER-\u03b1\u2013SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence","volume":"13","author":"M Mc Ilroy","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"pone.0289902.ref022","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas","volume":"24","author":"LV Pham","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"pone.0289902.ref023","article-title":"Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma","author":"L Li","year":"2022","journal-title":"haematol"},{"key":"pone.0289902.ref024","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.3390\/cancers14133229","article-title":"Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma","volume":"14","author":"K Saleh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"pone.0289902.ref025","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1080\/10428190500221454x","article-title":"The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma","volume":"46","author":"MJ Passineau","year":"2005","journal-title":"Leukemia & Lymphoma"},{"key":"pone.0289902.ref026","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.4049\/jimmunol.178.11.6840","article-title":"CD4+CD25+ T Regulatory Cells Dominate Multiple Immune Evasion Mechanisms in Early but Not Late Phases of Tumor Development in a B Cell Lymphoma Model","volume":"178","author":"KG Elpek","year":"2007","journal-title":"The Journal of Immunology"},{"key":"pone.0289902.ref027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13058-022-01568-2","article-title":"Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment","volume":"24","author":"SJ Han","year":"2022","journal-title":"Breast Cancer Res"},{"key":"pone.0289902.ref028","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1038\/s41598-021-82945-3","article-title":"Steroid receptor coactivator 3 (SRC-3\/AIB1) is enriched and functional in mouse and human Tregs","volume":"11","author":"BC Nikolai","year":"2021","journal-title":"Sci Rep"},{"key":"pone.0289902.ref029","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1535-7163.MCT-07-2373","article-title":"Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins","volume":"7","author":"D Zhai","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"pone.0289902.ref030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.celrep.2012.11.023","article-title":"Gambogic Acid Is a Tissue-Specific Proteasome Inhibitor In Vitro and In Vivo","volume":"3","author":"X Li","year":"2013","journal-title":"Cell Reports"},{"key":"pone.0289902.ref031","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1158\/1535-7163.MCT-07-0147","article-title":"Gambogic acid inhibits the catalytic activity of human topoisomerase II\u03b1 by binding to its ATPase domain","volume":"6","author":"Y Qin","year":"2007","journal-title":"Molecular Cancer Therapeutics"},{"key":"pone.0289902.ref032","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1038\/sj.emboj.7601106","article-title":"Absence of the steroid receptor coactivator-3 induces B-cell lymphoma","volume":"25","author":"A Coste","year":"2006","journal-title":"EMBO J"},{"issue":"Suppl 1","key":"pone.0289902.ref033","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.2860","article-title":"Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches","volume":"39","author":"E Silkenstedt","year":"2021","journal-title":"Hematol Oncol"},{"key":"pone.0289902.ref034","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12020-021-02819-6","article-title":"NCOA3 is a critical oncogene in thyroid cancer via the modulation of major signaling pathways","volume":"75","author":"Y Li","year":"2022","journal-title":"Endocrine"},{"key":"pone.0289902.ref035","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1038\/onc.2014.409","article-title":"NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer","volume":"34","author":"S Kumar","year":"2015","journal-title":"Oncogene"},{"key":"pone.0289902.ref036","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1158\/0008-5472.CAN-07-1013","article-title":"Epidermal Growth Factor Receptor Tyrosine Phosphorylation and Signaling Controlled by a Nuclear Receptor Coactivator, Amplified in Breast Cancer 1","volume":"67","author":"T Lahusen","year":"2007","journal-title":"Cancer Research"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0289902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:25:16Z","timestamp":1714397116000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0289902"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0289902","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2653461\/v1","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}